Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a pharmaceutical company focused on abuse-deterrent drug formulations for controlled substances, including opioids and stimulants. The company entered the public markets through a SPAC merger completed in 2021 and has since operated as a post-merger public company in the healthcare and biopharmaceutical sector. On August 6, 2026, Ensysce filed an amended current report on Form 8-K/A with the SEC under accession number 0001493152-26-036326, updating a prior disclosure. Analysts and investors tracking post-merger SPAC companies across the life sciences space can access Ensysce's complete filing history, deal timeline, and sponsor data by signing up for full coverage on SpacDesk.